Management of Primaquine-Induced Methemoglobinemia

Immediate Actions

Stop primaquine immediately upon recognition of methemoglobinemia, as this is the causative agent, and the patient can still achieve radical cure later with alternative strategies once the acute episode resolves 1, 2

Continue chloroquine (or alternative blood-stage antimalarial) to complete treatment of the acute infection, with chloroquine remaining first-line for P. vivax at 1000 mg salt initially, then 500 mg at 6, 24, and 48 hours, and alternative blood-stage treatments including artemether-lumefantrine or dihydroartemisinin-piperaquine if chloroquine resistance is suspected 1, 2

Once methemoglobin normalizes, consider weekly primaquine at 0.75 mg base/kg (maximum 45 mg) for 8 weeks with close monitoring, specifically recommended for patients with intermediate G6PD deficiency but can be applied to those with primaquine sensitivity, requiring weekly methemoglobin monitoring 1, 2
A single 300 mg dose of tafenoquine may be considered as an alternative, not available in Europe, approved only in the United States and Australia, requiring quantitative G6PD testing (must be >70% activity) 1, 2
In some cases, forgoing radical cure and treating relapses as they occur may be the safest approach, a reasonable strategy in non-endemic settings where reinfection risk is absent 1, 2

Retest for G6PD deficiency if not previously done, as G6PD deficiency increases risk of both hemolysis and methemoglobinemia, and monitor methemoglobin levels weekly if attempting modified primaquine regimen 1, 2
The Mediterranean G6PD variant (B-) has very high risk of severe complications with primaquine, and Asian populations may have higher rates of severe G6PD deficiency 1, 2, 3

The Centers for Disease Control and Prevention recommends that among populations where severe G6PD deficiency is common, primaquine should not be administered for greater than 5 days as administration for longer periods may result in life-threatening hemolysis 4, 5

The MMWR Recommendations and Reports suggest that in populations with high prevalence of severe G6PD deficiency, primaquine administration should be limited to 5 days to avoid life-threatening hemolysis, highlighting the need for alternative strategies in these patients 4, 5

Anti‑HAV IgG reflects past, resolved hepatitis A infection and does not indicate active disease, making hepatitis A an unlikely cause of recurrent jaundice. (Centers for Disease Control and Prevention) 6
Reactivation of hepatitis A does not occur in immunocompetent individuals. (Centers for Disease Control and Prevention) 7

Primaquine produces dose‑dependent hemolysis in patients with G6PD deficiency, which can manifest as jaundice due to indirect hyperbilirubinemia. (Centers for Disease Control and Prevention) 6, 7, 8

Patients with severe G6PD deficiency should not be given standard primaquine regimens. (Clinical Microbiology and Infection) 9